SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (482)6/15/1999 7:15:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 550
 
CNBC had a brief segment on PNU's buyout of SUGN. A synopsis is linked to the CNBC Specials page at pharmacognizance.com



To: margie who wrote (482)6/15/1999 8:56:00 PM
From: Miljenko Zuanic  Read Replies (3) | Respond to of 550
 
PNU has good cancer drugs portfolio, and investor projected aggressive EPS growth.

I may hold part of my SUGN holding.

This is second acquisition (from my core holding) in last few months. If this continue, I will be out of idea and have to start all over again.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News